Tvardi Therapeutics, Inc. financial data

Symbol
TVRD on Nasdaq
Location
Sugar Land, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 455% % -15%
Quick Ratio 11% % -17%
Debt-to-equity -84% % 2.5%
Return On Equity 199% % 184%
Return On Assets -166% % -188%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9,381,344 shares -83%
Common Stock, Shares, Outstanding 9,379,332 shares -83%
Entity Public Float $12,141,593 USD -91%
Common Stock, Value, Issued $9,000 USD -83%
Weighted Average Number of Shares Outstanding, Basic 9,377,079 shares 264%
Weighted Average Number of Shares Outstanding, Diluted 9,377,079 shares 264%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $7,571,000 USD -55%
Research and Development Expense $9,243,000 USD -85%
General and Administrative Expense $28,217,000 USD 89%
Operating Income (Loss) $33,053,000 USD 56%
Income Tax Expense (Benefit) $398,000 USD
Net Income (Loss) Attributable to Parent $65,116,000 USD -33%
Earnings Per Share, Basic 6 USD/shares 72%
Earnings Per Share, Diluted 4 USD/shares 72%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $21,418,000 USD -42%
Cash, Cash Equivalents, and Short-term Investments $37,903,000 USD -62%
Accounts Receivable, after Allowance for Credit Loss, Current $1,229,000 USD -28%
Inventory, Net $900,000 USD -67%
Assets, Current $38,443,000 USD -20%
Property, Plant and Equipment, Net $60,000 USD -98%
Operating Lease, Right-of-Use Asset $163,000 USD
Intangible Assets, Net (Excluding Goodwill) $338,000 USD
Other Assets, Noncurrent $17,000 USD
Assets $39,021,000 USD -24%
Accounts Payable, Current $4,078,000 USD 60%
Employee-related Liabilities, Current $1,014,000 USD
Accrued Liabilities, Current $6,849,000 USD
Liabilities, Current $11,040,000 USD 10%
Operating Lease, Liability, Noncurrent $115,000 USD
Liabilities $11,155,000 USD -78%
Accumulated Other Comprehensive Income (Loss), Net of Tax $7,000 USD
Retained Earnings (Accumulated Deficit) $103,175,000 USD 86%
Stockholders' Equity Attributable to Parent $27,866,000 USD
Liabilities and Equity $39,021,000 USD -24%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,692,000 USD 85%
Net Cash Provided by (Used in) Financing Activities $1,006,000 USD
Net Cash Provided by (Used in) Investing Activities $25,951,000 USD 47%
Common Stock, Shares Authorized 150,000,000 shares -25%
Common Stock, Shares, Issued 9,379,332 shares -83%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $21,418,000 USD 127%
Deferred Tax Assets, Valuation Allowance $200,656,000 USD 4.1%
Deferred Tax Assets, Gross $200,656,000 USD 3.4%
Operating Lease, Liability $228,000 USD
Payments to Acquire Property, Plant, and Equipment $836,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $33,753,000 USD 55%
Lessee, Operating Lease, Liability, to be Paid $249,000 USD
Operating Lease, Liability, Current $113,000 USD -97%
Lessee, Operating Lease, Liability, to be Paid, Year Two $88,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $129,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Income Tax Expense (Benefit) $0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $21,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,363,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $122,727,000 USD -0.82%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) $0 USD
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,398,000 USD
Operating Lease, Payments $50,000 USD 0%
Additional Paid in Capital $131,025,000 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $0 USD -100%
Share-based Payment Arrangement, Expense $339,000 USD 324%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%